[go: up one dir, main page]

WO2006125765A3 - Acylated insulin with high purity - Google Patents

Acylated insulin with high purity Download PDF

Info

Publication number
WO2006125765A3
WO2006125765A3 PCT/EP2006/062495 EP2006062495W WO2006125765A3 WO 2006125765 A3 WO2006125765 A3 WO 2006125765A3 EP 2006062495 W EP2006062495 W EP 2006062495W WO 2006125765 A3 WO2006125765 A3 WO 2006125765A3
Authority
WO
WIPO (PCT)
Prior art keywords
insulin
acylated insulin
high purity
weight
acylated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2006/062495
Other languages
French (fr)
Other versions
WO2006125765A2 (en
Inventor
Jan Markussen
Svend Havelund
Jes Kristian Jacobsen
Aage Hvass
Ib Jonassen
Georg Wilhelm Jensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Priority to EP06763218A priority Critical patent/EP1888104A2/en
Publication of WO2006125765A2 publication Critical patent/WO2006125765A2/en
Publication of WO2006125765A3 publication Critical patent/WO2006125765A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention is related to a highly purified pharmaceutical preparation comprising an acylated insulin where the acyl group is attached via a linker molecule to the ϵ- amino group of the B29Lys residue of the parent insulin moiety. The insulin pharmaceutical formulation comprises less than about 3% weight/weight of an isomer of the acylated insulin.
PCT/EP2006/062495 2005-05-26 2006-05-22 Acylated insulin with high purity Ceased WO2006125765A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP06763218A EP1888104A2 (en) 2005-05-26 2006-05-22 Acylated insulin with high purity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200500767 2005-05-26
DKPA200500767 2005-05-26

Publications (2)

Publication Number Publication Date
WO2006125765A2 WO2006125765A2 (en) 2006-11-30
WO2006125765A3 true WO2006125765A3 (en) 2007-02-15

Family

ID=37269816

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2006/062495 Ceased WO2006125765A2 (en) 2005-05-26 2006-05-22 Acylated insulin with high purity

Country Status (2)

Country Link
EP (1) EP1888104A2 (en)
WO (1) WO2006125765A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3341401A1 (en) 2015-08-25 2018-07-04 Novo Nordisk A/S Novel insulin derivatives and the medical uses hereof
CN108368163A (en) 2015-08-25 2018-08-03 诺和诺德股份有限公司 Novel insulin derivates and its medical usage
WO2020069040A1 (en) * 2018-09-25 2020-04-02 Amphastar Pharmaceuticals, Inc. Highly purified recombinant human insulin (rhi) api and methods of producing the same
JP2022501546A (en) 2018-10-01 2022-01-06 ベーリンガー インゲルハイム フェトメディカ ゲーエムベーハーBoehringer Ingelheim Vetmedica GmbH Peristaltic pumps and analyzers for inspecting samples

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
WO1999021888A1 (en) * 1997-10-24 1999-05-06 Novo Nordisk A/S Aggregates of human insulin derivatives
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995007931A1 (en) * 1993-09-17 1995-03-23 Novo Nordisk A/S Acylated insulin
EP1132404A2 (en) * 1993-09-17 2001-09-12 Novo Nordisk A/S Acylated insulin
WO1999021888A1 (en) * 1997-10-24 1999-05-06 Novo Nordisk A/S Aggregates of human insulin derivatives
US20040138099A1 (en) * 2002-11-29 2004-07-15 Draeger Eberhard Kurt Insulin administration regimens for the treatment of subjects with diabetes

Also Published As

Publication number Publication date
WO2006125765A2 (en) 2006-11-30
EP1888104A2 (en) 2008-02-20

Similar Documents

Publication Publication Date Title
TW200833326A (en) Chemical compounds 572
JP2019523228A (en) Process, pharmaceutical formulation and use thereof for the production of cannabinoid prodrugs
Aiello et al. Clavaminols A–F, novel cytotoxic 2-amino-3-alkanols from the ascidian Clavelina phlegraea
US20160297840A1 (en) Stable pantetheine derivatives for the treatment of pantothenate kinase associated neurodegeneration (pkan) and methods for the synthesis of such compounds
WO2007083060A3 (en) Novel chalcone derivatives with antimitotic activity
WO2006125765A3 (en) Acylated insulin with high purity
AR048973A1 (en) (4-METOXI-7-MORFOLIN-4-IL-BENZOTIAZOL-2-IL) AMID OF THE ACID 4-HYDROXY-4-METHYL-PIPERIDIN-1-CARBOXYL. PHARMACEUTICAL PREPARATION AND COMPOSITION PROCESS
WO2005062985A3 (en) Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
SI1831186T1 (en) A process for the synthesis of valsartan
WO2008012442A3 (en) Mixture of partial esters of monopentaerythritol, dipentaerythritol and tripentaerythritol, process for obtaining same and cosmetic product containing them
JP4233262B2 (en) Carbasugar amine derivatives and glycosidase inhibitors using the same
ES2655655T3 (en) Preparation procedure for alpha-galactosyl ceramide compounds
WO2008059513A3 (en) Compounds suitable as modulators of hdl
WO2007075838A3 (en) Pure and stable tiotropium bromide
Zamyatina et al. Synthesis and purity assessment of tetra-and pentaacyl lipid A of Chlamydia containing (R)-3-hydroxyicosanoic acid
Washington et al. Exploiting translational stalling peptides in an effort to extend azithromycin interaction within the prokaryotic ribosome nascent peptide exit tunnel
UA92833C2 (en) Pyrazole analogues
WO2008049996A3 (en) Novel indole derivatives, process for the preparation thereof and pharmaceutical compositions containing them
GB0208176D0 (en) Organic compounds
CA2273374C (en) Trioxane dimer compounds having antiproliferative and antitumor activities
USRE38117E1 (en) Trioxane dimer compound having antiproliferative and antitumor activities
Bera et al. Chemical synthesis of the pentasaccharide related to the anti-inflammatory oleanane type saponins isolated from medicinal plant Aster tataricus L. f.
WO2008053295A3 (en) Pharmaceutical compositions of benzoquinolizine-2-carboxylic acid
BR0315265A (en) Pharmacologically active dauer pheromone compound to control aging and stress and method to isolate and characterize it
US6004997A (en) Trioxane dimer compounds having antiproliferative and antitumor activities

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006763218

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006763218

Country of ref document: EP